Compile Data Set for Download or QSAR
Report error Found 653 Enz. Inhib. hit(s) with Target = 'Complement factor B'
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160272(US9682968, Example-22-2b (-))
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160485(US9682968, Example-27-4a (+))
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160483(US9682968, Example-27-3a (-))
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159970(US9682968, Example-20a | US10093663, Example 20a)
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159545(US9682968, Example-17-30 | US9682968, Example-17-1...)
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160475(US9682968, Example-26a | US10093663, Example 26b |...)
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159938(US9682968, Example-17-29 | US10093663, Example 17-...)
Affinity DataIC50: 0.0100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159486(US9682968, Example-17-11 | US10093663, Example 17-...)
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160500(US9682968, Example-37 | US10093663, Example 37)
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160499(US9682968, Example-36 | US10093663, Example 36)
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160102(US9682968, Example-22-1a (-))
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160036(US9682968, Example-21a | US10093663, Example 21a)
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160481(US9682968, Example-27-2a (+))
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159312(US9682968, Example-17-1 | US10093663, Example 17-1)
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160480(US9682968, Example-27-1b (-))
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159545(US9682968, Example-17-30 | US9682968, Example-17-1...)
Affinity DataIC50: 0.0200nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159319(US9682968, Example-17-5)
Affinity DataIC50: 0.0300nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159566(US9682968, Example-17-18 | US10093663, Example 17-...)
Affinity DataIC50: 0.0300nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159311(US9682968, Example-16 | US10093663, Example 16)
Affinity DataIC50: 0.0300nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159873(US9682968, Example-17-24 | US10093663, Example 17-...)
Affinity DataIC50: 0.0400nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159289(US9682968, Example-5-12 | US10093663, Example 5-12)
Affinity DataIC50: 0.0400nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159314(US9682968, Example-17-3)
Affinity DataIC50: 0.0400nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159920(US9682968, Example-17-25 | US10093663, Example 17-...)
Affinity DataIC50: 0.0500nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160474(US9682968, Example-25b (-))
Affinity DataIC50: 0.0500nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160506(US9682968, Example-40 | US10093663, Example 40)
Affinity DataIC50: 0.0600nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159509(US9682968, Example-17-13 | US10093663, Example 17-...)
Affinity DataIC50: 0.0600nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159379(US9682968, Example-17-8 | US10093663, Example 17-8)
Affinity DataIC50: 0.0700nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159316(US9682968, Example-17-4)
Affinity DataIC50: 0.0900nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159382(US9682968, Example-17-10 | US10093663, Example 17-...)
Affinity DataIC50: 0.100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159841(US9682968, Example-17-22 | US10093663, Example 17-...)
Affinity DataIC50: 0.100nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159313(US9682968, Example-17-2)
Affinity DataIC50: 0.120nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160501(US9682968, Example-38 | US10093663, Example 38)
Affinity DataIC50: 0.130nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159303(US9682968, Example-13 | US10093663, Example 13)
Affinity DataIC50: 0.140nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159932(US9682968, Example-17-28 | US10093663, Example 17-...)
Affinity DataIC50: 0.160nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

LigandPNGBDBM761323(US20250243186, Example 57)
Affinity DataKd:  0.170nMAssay Description:Table 2: Biacore 8 k instrument was primed using 1× PBS-P+ buffer before docking a Cytiva NTA chip. Recombinant human Factor B catalytic domain were ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160507(US9682968, Example-41)
Affinity DataIC50: 0.170nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159157(US9682968, Example-5-4 | US10093663, Example 5-4)
Affinity DataIC50: 0.180nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159301(US9682968, Example-11)
Affinity DataIC50: 0.230nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160508(US9682968, Example-42 | US10093663, Example 42)
Affinity DataIC50: 0.240nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160504(US9682968, Example-39-3 | US10093663, Example 39-3)
Affinity DataIC50: 0.280nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159976(US9682968, Example-20b | US10093663, Example 20b)
Affinity DataIC50: 0.290nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160505(US9682968, Example-39-4 | US10093663, Example 39-4)
Affinity DataIC50: 0.300nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM160495(US9682968, Example-32-3 | US10093663, Example 32-3)
Affinity DataIC50: 0.340nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

LigandPNGBDBM732751((S)-4-(7-((5-cyclopropyl-7-methyl-1H-indol-4-yl)me...)
Affinity DataKd:  0.380nMAssay Description:Table 2: Biacore 8 k instrument was primed using 1× PBS-P+ buffer before docking a Cytiva NTA chip. Recombinant human Factor B catalytic domain were ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159506(US9682968, Example-17-12 | US10093663, Example 17-...)
Affinity DataIC50: 0.450nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM732731(US20250115572, Ex-1)
Affinity DataIC50: 0.5nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/22/2025
Entry Details

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM732735((S)-4-(2,2-difluoro-7-((5-methoxy-7-methyl-1H-indo...)
Affinity DataIC50: 0.5nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/22/2025
Entry Details

LigandPNGBDBM761325(US20250243186, Example 47)
Affinity DataKd:  0.530nMAssay Description:Table 2: Biacore 8 k instrument was primed using 1× PBS-P+ buffer before docking a Cytiva NTA chip. Recombinant human Factor B catalytic domain were ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM732785(US20250115572, Ex-55)
Affinity DataIC50: 0.600nMAssay Description:TBDMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/22/2025
Entry Details

TargetComplement factor B(Human)
Novartis

US Patent
LigandPNGBDBM159296(US9682968, Example-9-2 | US10093663, Example 9-2)
Affinity DataIC50: 0.640nMAssay Description:CVF-Bb complex prepared from purified cobra venom factor (1 uM), recombinant human complement factor B (expressed in drosophila cells and purified us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/13/2018
Entry Details
US Patent

Displayed 1 to 50 (of 653 total ) | Next | Last >>
Jump to: